CRTX vs. SGMO, ADVM, CHRS, SRRK, FMTX, OMCL, MDRX, HSTM, BLUE, and ATHA Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Scholar Rock (SRRK), Forma Therapeutics (FMTX), Omnicell (OMCL), Veradigm (MDRX), HealthStream (HSTM), bluebird bio (BLUE), and Athira Pharma (ATHA).
Cortexyme (NASDAQ:CRTX ) and Sangamo Therapeutics (NASDAQ:SGMO ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
In the previous week, Sangamo Therapeutics had 3 more articles in the media than Cortexyme. MarketBeat recorded 3 mentions for Sangamo Therapeutics and 0 mentions for Cortexyme. Sangamo Therapeutics' average media sentiment score of 1.09 beat Cortexyme's score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Sangamo Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 904.02%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Cortexyme.
Cortexyme has higher earnings, but lower revenue than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.
Cortexyme has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -1,749.06%. Cortexyme's return on equity of -70.96% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics received 285 more outperform votes than Cortexyme when rated by MarketBeat users. However, 64.44% of users gave Cortexyme an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Summary Cortexyme beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cortexyme Competitors List
Related Companies and Tools
